- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06843590
En undersøgelse til evaluering af sikkerheden og effektiviteten af ALKS 2680 hos personer med idiopatisk hypersomnia (Vibrance-3)
En fase 2, randomiseret, parallel-gruppe, dobbeltblind, dosis-finding-undersøgelse for at evaluere sikkerheden og effektiviteten af ALKS 2680 hos personer med idiopatisk hypersomnia (Vibrance-3)
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2113
- Alkermes Investigator Site
-
-
South Australia
-
Bedford Park, South Australia, Australien, 5042
- Alkermes Investigator Site
-
-
Victoria
-
Clayton, Victoria, Australien, 3168
- Alkermes Investigator Site
-
-
-
-
-
Alken, Belgien, 3570
- Alkermes Investigator Site
-
Namur, Belgien, 5101
- Alkermes Investigator Site
-
-
-
-
Alabama
-
Cullman, Alabama, Forenede Stater, 35055
- Alkermes Investigator Site
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Alkermes Investigator Site
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Alkermes Investigator Site
-
-
California
-
Los Angeles, California, Forenede Stater, 90025
- Alkermes Investigator Site
-
Redwood City, California, Forenede Stater, 94063
- Alkermes Investigator Site
-
San Francisco, California, Forenede Stater, 94143
- Alkermes Investigator Site
-
-
Colorado
-
Boulder, Colorado, Forenede Stater, 80301
- Alkermes Investigational Site
-
Colorado Springs, Colorado, Forenede Stater, 80918
- Alkermes Investigator Site
-
-
Florida
-
Brandon, Florida, Forenede Stater, 33511
- Alkermes Investigator Site
-
Miami, Florida, Forenede Stater, 33176
- Alkermes Investigator Site
-
Winter Park, Florida, Forenede Stater, 32789
- Alkermes Investigator Site
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30328
- Alkermes Investigator Site
-
Macon, Georgia, Forenede Stater, 31210
- Alkermes Investigator Site
-
Stockbridge, Georgia, Forenede Stater, 30281
- Alkermes Investigator Site
-
-
Illinois
-
Peoria, Illinois, Forenede Stater, 61637
- Alkermes Investigator Site
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Alkermes Investigator Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Alkermes Investigational Site
-
-
Michigan
-
Lansing, Michigan, Forenede Stater, 48911
- Alkermes Investigator Site
-
-
Nebraska
-
Lincoln, Nebraska, Forenede Stater, 68506
- Alkermes Investigator Site
-
-
New Jersey
-
Middletown, New Jersey, Forenede Stater, 07748
- Alkermes Investigator Site
-
-
North Carolina
-
Denver, North Carolina, Forenede Stater, 28037
- Alkermes Investigator Site
-
Huntersville, North Carolina, Forenede Stater, 28078
- Alkermes Investigator Site
-
-
Ohio
-
Canton, Ohio, Forenede Stater, 44718
- Alkermes Investigator Site
-
Cincinnati, Ohio, Forenede Stater, 45245
- Alkermes Investigator Site
-
Cleveland, Ohio, Forenede Stater, 44195
- Alkermes Investigator Site
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822
- Alkermes Investigator Site
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Alkermes Investigator Site
-
Wyomissing, Pennsylvania, Forenede Stater, 19610
- Alkermes Investigator Site
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29201
- Alkermes Investigator Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78731
- Alkermes Investigator Site
-
San Antonio, Texas, Forenede Stater, 78229
- Alkermes Investigator Site
-
Sugar Land, Texas, Forenede Stater, 77478
- Alkermes Investigator Site
-
Sugarland, Texas, Forenede Stater, 77478
- Alkermes Investigator Site
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Alkermes Investigator Site
-
-
-
-
Gironde
-
Bordeaux, Gironde, Frankrig, 33000
- Alkermes Investigator Site
-
-
Herault
-
Montpellier, Herault, Frankrig, 34295
- Alkermes Investigator Site
-
-
Isere
-
Grenoble, Isere, Frankrig, 38043
- Alkermes Investigator Site
-
-
-
-
-
Zwolle, Holland, 8025 BV
- Alkermes Investigator Site
-
-
-
-
-
Bologna, Italien, 40139
- Alkermes Investigator Site
-
Milan, Italien, 20127
- Alkermes Investigator Site
-
Verona, Italien, 37134
- Alkermes Investigator Site
-
-
-
-
-
Barcelona, Spanien, 8036
- Alkermes Investigator Site
-
Madrid, Spanien, 28036
- Alkermes Investigator Site
-
Madrid, Spanien, 28043
- Alkermes Investigator Site
-
-
-
-
-
Prague, Tjekkiet, 128 21
- Alkermes Investigator Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including: lifestyle considerations and restrictions, adherence to contraception guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits.
- Meets the diagnostic criteria of Idiopathic Hypersomnia according to ICSD-3-TR guidelines, confirmed by the diagnostic evaluations (PSG/MSLT/actigraphy) within the previous 10 years
Exclusion Criteria:
- Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle
- Has a history or presence at Visit 1 of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise subject safety, interfere with any study assessment, or affect the subject's ability to complete the study
- Is currently enrolled in another clinical study or used any investigational drug or device within 30 days prior to Visit 1
- Is currently pregnant, breastfeeding, or is planning to become pregnant during the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ALKS 2680, 10 mg- Part A
Oral tablet containing 10 mg of ALKS 2680 for once daily administration |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
Eksperimentel: ALKS 2680, 14 mg -Part A
Oral tablet containing 14 mg of ALKS 2680 for once daily administration |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
Eksperimentel: ALKS 2680, 18 mg- Part A
Oral tablet containing 18 mg of ALKS 2680 for once daily administration |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
Placebo komparator: Placebo- Part A
Oral placebo tablet for once daily administration |
Oral placebo tablet for daily administration |
|
Eksperimentel: ALKS 2680 Dose 1- Part B
Oral tablets of ALKS 2680 taken, orally, daily |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
Placebo komparator: Placebo - Part B
Oral tablets of placebo taken, orally, daily |
Oral placebo tablet for daily administration |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring i Epworth Sleepiness Scale (ESS) fra baseline til uge 8 efter dosisniveau
Tidsramme: Op til 8 uger
|
Op til 8 uger
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring i idiopatisk hypersomnia sværhedsgrad (IHSS) fra baseline til uge 8 efter dosisniveau
Tidsramme: Op til 8 uger
|
Op til 8 uger
|
|
Incidence of treatment emergent adverse events
Tidsramme: Up to 10 weeks
|
Up to 10 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Medical Director, Alkermes, Inc.
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ALKS 2680-203
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .